Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: Help from modern physics in the management of an ancient disease

A. Kirstin Bacani, Cynthia H McCollough, Katrina Nesta Glazebrook, Jeffrey R. Bond, Clement Michet, Jeffrey Milks, Nisha J. Manek

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403-2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1β inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.

Original languageEnglish (US)
Pages (from-to)235-239
Number of pages5
JournalRheumatology International
Volume32
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Gout
Physics
Disease Management
Uric Acid
Tomography
Therapeutics
Allopurinol
United States Food and Drug Administration
Interleukin-1
Arthritis
Technology
Incidence

Keywords

  • Anakinra
  • Dual energy computed tomography
  • Gout
  • Rasburicase
  • Uricolytic

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

@article{2b822b79214143f491c94ec9f2b171ee,
title = "Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: Help from modern physics in the management of an ancient disease",
abstract = "Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403-2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1β inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.",
keywords = "Anakinra, Dual energy computed tomography, Gout, Rasburicase, Uricolytic",
author = "Bacani, {A. Kirstin} and McCollough, {Cynthia H} and Glazebrook, {Katrina Nesta} and Bond, {Jeffrey R.} and Clement Michet and Jeffrey Milks and Manek, {Nisha J.}",
year = "2012",
month = "1",
doi = "10.1007/s00296-009-1295-7",
language = "English (US)",
volume = "32",
pages = "235--239",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout

T2 - Help from modern physics in the management of an ancient disease

AU - Bacani, A. Kirstin

AU - McCollough, Cynthia H

AU - Glazebrook, Katrina Nesta

AU - Bond, Jeffrey R.

AU - Michet, Clement

AU - Milks, Jeffrey

AU - Manek, Nisha J.

PY - 2012/1

Y1 - 2012/1

N2 - Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403-2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1β inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.

AB - Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403-2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1β inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.

KW - Anakinra

KW - Dual energy computed tomography

KW - Gout

KW - Rasburicase

KW - Uricolytic

UR - http://www.scopus.com/inward/record.url?scp=84857123196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857123196&partnerID=8YFLogxK

U2 - 10.1007/s00296-009-1295-7

DO - 10.1007/s00296-009-1295-7

M3 - Article

C2 - 20016988

AN - SCOPUS:84857123196

VL - 32

SP - 235

EP - 239

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 1

ER -